VIB-RUG Department of Molecular Biomedical Research

Molecular ImmunoBiotechnology Unit

 

 

 

 

 

 

 

 

 

Clinical Results obtained with Bispecific Antibodies

 

                    Under construction...

 

ClinicalTrials.gov: Linking Patients to Medical Research

Ongoing Clinical Trails with BsAb

bulletAntibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (MDX447)
bulletBispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme (4G7xH22)
bullet2002: A Phase II study to determine the biological effects of bispecific antibody MDX-H210 (520C9XH22) combined with GM-CSF in patients with advanced prostate cancer or renal cell carcinomas that express HER2/neu.

American Society of Clinical Oncology

Bispecific Antibody Clinical Trail Abstracts

 

bullet1997: A phase I trial of bispecific antibody (BsAB) MDX447 without and with granulocyte colony-stimulating factor (G-CSF) in patients with adult solid tumors.
bullet1998: PHASE I TRIAL OF BISPECIFIC ANTIBODY MDX-H210 (FcgammaRI × HER-2/NEU) IN COMBINATION WITH G-CSF IN PATIENTS WITH STAGE IV METASTATIC BREAST CANCER.
bullet1998: PHASE II TRIAL OF THE BISPECIFIC ANTIBODY MDX-H210 (ANTI-HER2/NEU X ANTI-CD64) COMBINED WITH GM-CSF IN PATIENTS WITH ADVANCED PROSTATE AND RENAL CELL CARCINOMAS THAT EXPRESS HER2/NEU.
bullet1998: MYELOABLATIVE CHEMOTHERAPY, STEM CELL TRANSPLANTATION, T-CELL REINFUSION AND REDIRECTING BISPECIFIC ANTIBODIES IN PATIENTS WITH METASTATIC BREAST CANCER: A PHASE I TRIAL
bullet1998: TREATMENT OF REFRACTORY HODGKIN'S DISEASE (HD) WITH AN ANTI-CD30/CD16 BISPECIFIC MONOCLONAL ANTIBODY (BiMAb)
bullet1999: Immunotherapy with the Bispecific Antibody MDX-H210 (anti-HER2 × anti-CD64) Combined with GM-CSF in HER2 Positive Hormone Resistant Prostatic Cancer.
bullet1999: A Phase I Trial of the Epidermal Growth Factor Receptor (EGFR)-Directed Bispecific Antibody (BsAB) MDX-447 in Patients with Solid Tumors.
bullet2000: Phase I Trial of Bispecific Antibody MDX-H210 (FcgammaRI X HER-2/neu) up to High Doses in Combination with G-CSF in Patients with Metastatic Breast Cancer.
bullet2000: Adoptive Immunotherapy in Ovarian Cancer with Monocyte Derived Activated Killer Cells Mixed with Anti HER2/neu + Anti Fc Gamma RI Bispecific Antibody.
 
Home

Contact

Research projects

Publications

After eight

Check out 

links to:
MABs on the market
Antibody Companies
Immune Therapy Companies
Custom protein expression and purification
Biotech in Flanders
Flanders Universities
Flanders Biotech Policy

                  

© 2002 Webmaster